Mirati Therapeutics, Inc. (MRTX)
(Delayed Data from NSDQ)
$195.60 USD
-7.30 (-3.60%)
Updated Feb 25, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
4-Sell of 5 4
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
D Value F Growth D Momentum F VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
View All Zacks #1 Ranked Stocks
Zacks News
Amgen (AMGN) Files for KRAS Inhibitor for Lung Cancer in Europe
by Zacks Equity Research
The regulatory filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which shows that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.
JNJPositive Net Change LLYNegative Net Change AMGNNegative Net Change MRTXNegative Net Change
pharmaceuticals
Amgen (AMGN) Submits NDA for KRAS Inhibitor for Lung Cancer
by Zacks Equity Research
The NDA filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which showed that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.
JNJPositive Net Change LLYNegative Net Change AMGNNegative Net Change MRTXNegative Net Change
biotechs
Amgen's (AMGN) KRAS Inhibitor Gets Breakthrough Tag for NSCLC
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy status on Amgen's (AMGN) KRAS inhibitor, sotorasib, for treating patients with advanced/metastatic non-small-cell lung cancer with KRAS G12C mutation.
JNJPositive Net Change LLYNegative Net Change AMGNNegative Net Change MRTXNegative Net Change
biotechs
Why Is Mirati (MRTX) Down 2.2% Since Last Earnings Report?
by Zacks Equity Research
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MRTXNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mirati (MRTX) delivered earnings and revenue surprises of 3.92% and 1580.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
MRTXNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Why Mirati Therapeutics (MRTX) Might Surprise This Earnings Season
by Zacks Equity Research
Mirati Therapeutics (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
MRTXNegative Net Change
medical
Mirati (MRTX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MRTXNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Mirati (MRTX) Up 6.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MRTXNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Analysts Estimate Mirati (MRTX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MRTXNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Mirati (MRTX) Up 4.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MRTXNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Mirati (MRTX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Mirati (MRTX) delivered earnings and revenue surprises of -22.42% and -58.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
MRTXNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Analysts Estimate Mirati (MRTX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MRTXNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
4 Drug/Biotech Outperformers That May Lose Steam in 2020
by Kinjel Shah
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
MRTXNegative Net Change ANIPNegative Net Change IMMUNegative Net Change PTCTNegative Net Change
pharmaceuticals
Options Traders Expect Huge Moves in Mirati (MRTX) Stock
by Zacks Equity Research
Investors need to pay close attention to Mirati (MRTX) stock based on the movements in the options market lately.
MRTXNegative Net Change
medical
Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mirati (MRTX) delivered earnings and revenue surprises of -8.66% and 97.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
MRTXNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Are Options Traders Betting on a Big Move in Mirati Therapeutics (MRTX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.
MRTXNegative Net Change
medical
Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group
by Zacks Equity Research
Amgen's (AMGN) novel investigational KRAS inhibitor, AMG 510, for solid tumor shows anti-tumor activity in a larger group of NSCLC patients.
ALXNNegative Net Change AMGNNegative Net Change BIIBNegative Net Change MRTXNegative Net Change
biotechs
Mirati Inks Deal with Novartis to Evaluate Tumor Candidate
by Zacks Equity Research
Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.
AMGNNegative Net Change MRTXNegative Net Change ALNYNegative Net Change AGTCNegative Net Change
biotechs
Implied Volatility Surging for Mirati Therapeutics (MRTX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.
MRTXNegative Net Change
biotechs
Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity
by Zacks Equity Research
At ASCO, Amgen (AMGN) presented encouraging initial data set for AMG 510, its novel investigational KRAS inhibitor for solid tumor.
RHHBYNegative Net Change BMYNegative Net Change AMGNNegative Net Change MRTXNegative Net Change
biotechs
Why Cancer-Fighting Stocks & ETFs Are Soaring
by Neena Mishra
The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
LLYNegative Net Change AZNNegative Net Change BMYNegative Net Change MRKPositive Net Change CNCRNegative Net Change CELGPositive Net Change MRTXNegative Net Change AMGNNegative Net Change NKTRNegative Net Change IOVANegative Net Change CHNANegative Net Change
medical
Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock
by Zacks Equity Research
Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.
MRTXNegative Net Change
medical
Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
MRTXNegative Net Change ACORNegative Net Change
biotechs
Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy
by Neena Mishra
2018 Nobel Prize for medicine was awarded for immunotherapy research. Here is what investors need to know about stocks and ETF focused on this innovative area.
CNCRNegative Net Change BLUEPositive Net Change FPRXNegative Net Change MRTXNegative Net Change FATENegative Net Change CHNANegative Net Change
biotechs etfs medical
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DWAS
DWASNegative Net Change PLUSNegative Net Change MRTXNegative Net Change CDNAPositive Net Change